Valeant Shares Surge on Guidance Despite Profit Drop

Valeant Pharmaceuticals reported second-quarter profit that fell below expectations, but the drugmaker maintained its full-year guidance and plans to sell assets worth about $8 billion. Bloomberg's Cynthia Koons recaps second-quarter results and what was learned on this morning's conference call. She speaks on "Bloomberg Markets." (Source: Bloomberg)

Full Show: Bloomberg Real Yield (09/15)
16:24 - Guests include: George Rusnak, Wells Fargo Investment Institute co-head of global fixed-income strategy, Kathy Jones, Schwab Center for Financial Research chief fixed-income strategist, and Matt Brill, Invesco senior portfolio manager. (Source: Bloomberg)
  • Full Show: Bloomberg Daybreak: Americas (09/15)
  • No Need for Germany to Issue Debt, Says Jefferies' Zervos
  • Full Show: Bloomberg Daybreak: Americas (09/14)